Drug
Apixaban
Apixaban: highest development phase Post-Market, developed by Bristol-Myers Squibb. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Bristol-Myers Squibb
Trials
| Drug | Phase | Indication |
|---|---|---|
| Apixaban NCT01884350 | Post-Market | Non-valvular Atrial Fibrillation |
| Apixaban NCT02889562 | Phase 2/3 | Coronary Artery Bypass Grafting |
Latest
No recent events.
Follow Apixaban on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.